NEW YORK (GenomeWeb News) – Cancer diagnostic development firm DiagnoCure said after the close of the market on Friday that its fiscal fourth-quarter revenues fell 59 percent year over year.

For the three months ended Oct. 31, the Quebec City, Quebec-based firm posted C$142,995 (US$145,306) in revenues, down from C$345,923 in Q4 2011. All revenues resulted from licensing agreements in the recently completed quarter, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.